Contact Elarex

OUR TECHNOLOGY

Patented and patent-pending formulation processes and simple mixtures which stabilize the vaccine or bio-therapeutic at up to 40°C as if it were frozen at -80°C.
bt_bb_section_bottom_section_coverage_image

XE120-L™Liquid Formulation Stabilization Technology

This formulation and process was invented in 2021 in the newly formed labs of Elarex. Building on our deep understanding of RNA, we focused on the challenge of stabilizing mRNA within lipid nanoparticles. The result is our proprietary XE120-L technology platform.
Figure 1.

Figure 1.

The key steps to making mRNA-LNPs. The focus of the Elarex R&D team has been to use the current industrial process as much as possible, so innovations that enable greater stabilization are easily adopted.

mRNA-LNPs

mRNA is notoriously unstable and unable to enter a cell without help.  The lipid nano-particle helped solve both problems simultaneously, but the resulting temperature stability is still not as good as other drugs and vaccines on the market today.  Formulating with XE120-L results in much better half-life of the mRNA, while protecting the LNP integrity.

PT120-D ™Formulation Stabilization Technology

The work on PT120-D started in the Filipe lab at McMaster University in 2014. During the course of this work, many different substances have been stabilized. Here are a few examples.

RNA

RNA is particularly unstable in the environment. It is prone to degradation by the ubiquitous RNAse enzyme, but also simply degrading by reacting with itself. The pullulan film prevents cleavage through both mechanisms.
Figure 1

Figure 1

Preventing RNA auto-cleavage at pH 7.5. Percentage cleavage of RS1 in solution and in pullulan film.
Figure 2

Figure 2

Preventing RNA auto-cleavage under alkaline conditions. Percentage cleavage of RS2 in alkaline solution and in alkaline pullulan film.

Viruses and Vaccines

Viruses are another example of unstable products, specifically in the face of higher temperatures. In the study below, attenuated herpes simplex virus and inactivated influenza A virus were stored in PT120-D and also in solution at -80°C and +40°C for 12 weeks. They were then used to inoculate mice and these mice were subsequently challenged with the live virus. The results show clearly that protection by PT120-D at 40°C, was as effective as freezing the vaccine at -80°C. The vaccine stored in solution at 40°C was also completely ineffective at protecting the mice.
Figure 1.

Figure 1.

HSV-2 Virus Stability at 25°C. Elarex PT120-D outperforms Trehalose 1000-fold at 12 weeks.
Figure 2.

Figure 2.

HSV-2 with Elarex PT120-D stored for 8 weeks at 40°C equivalent to storage at -80°C.
Figure 3.

Figure 3.

Inactivated IAV with Elarex PT120-D stored for 12 weeks at 40°C equivalent to storage at -80°C.
Figure 4.

Figure 4.

Immune response by ELISA for flu-specific IgG in serum. Equivalent responses for inactivated IAV stored at -80°C and when protected by PT120-D at 40°C for 12 weeks.

LetsConnect

    Name (required)*

    Email (required)*

    Phone (required)*

    Message

    Elarex formulation technology platforms are proven to dramatically improve temperature stabilization of biologicals, including vaccines so that they can be stored at 40°C and be as stable as they would be at -80°C

    Copyright © – © Elarex Inc. All rights reserved. | Website Developed & Managed by GlobeSign

    Connect With Us

    contact@elarexinc.com
    Burlington, ON